1. Home
  2. PLCE vs SPRO Comparison

PLCE vs SPRO Comparison

Compare PLCE & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Children's Place Inc. (The)

PLCE

Children's Place Inc. (The)

HOLD

Current Price

$2.54

Market Cap

72.5M

ML Signal

HOLD

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.17

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLCE
SPRO
Founded
1969
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.5M
71.0M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
PLCE
SPRO
Price
$2.54
$1.17
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
216.8K
437.4K
Earning Date
04-10-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
11.48
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.41
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$2.04
$1.08
52 Week High
$9.56
$3.08

Technical Indicators

Market Signals
Indicator
PLCE
SPRO
Relative Strength Index (RSI) 48.04 33.55
Support Level $2.35 $1.13
Resistance Level $2.88 $1.29
Average True Range (ATR) 0.19 0.04
MACD 0.04 0.02
Stochastic Oscillator 44.64 0.00

Price Performance

Historical Comparison
PLCE
SPRO

About PLCE Children's Place Inc. (The)

Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It designs, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names. The Company classifies its business into two segments: The Children's Place U.S. and The Children's Place International.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: